The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation.
Over the past 6 years, umbilical cord blood has emerged as an efficacious alternative source of hematopoietic stem cells in related bone marrow transplantation. These encouraging results led us to extend this technology to the mismatched related and unrelated settings in three high-risk leukemic children lacking a matched-related donor for transplantation. Two of the three children also lacked identifiable donors through the National Marrow Donor Program, while the third was in relapse and did not have time to wait for completion of a search. The first child was transplanted with haploidentical umbilical cord blood-derived mononuclear cells from his sister, while the remaining two children were transplanted with partially mismatched, unseparated, unrelated umbilical cord blood banked through the Placental Blood Project at the New York Blood Center. All three children demonstrated trilineage engraftment with donor cells within 6 weeks of transplantation. The patient transplanted with haploidentical marrow developed grade 2 graft vs. host disease (GVHD), which was controlled with steroid and anti-thymocyte globulin (ATG) therapy. One of the two patients grafted with unrelated umbilical cord blood developed mild grade 1 GVHD of the skin, which rapidly cleared with steroid therapy. One patient remains alive, in good health and disease-free 12 months from transplantation.
Kurtzberg
J
J
Pediatric Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA.
Graham
M
M
Casey
J
J
Olson
J
J
Stevens
C E
CE
Rubinstein
P
P
D000208:Acute Disease; D002648:Child; D002675:Child, Preschool; D017809:Fatal Outcome; D005260:Female; D005312:Fetal Blood / Q000166:cytology* / Q000276:immunology; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D007239:Infections / Q000209:etiology; D007951:Leukemia, Myeloid / Q000628:therapy*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000628:therapy*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011654:Pulmonary Edema / Q000209:etiology; D012074:Remission Induction; D016879:Salvage Therapy